Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.
PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for nerve pain (neuropathic pain), a condition currently lacking effective and safe treatment. The company is currently finalising its clinical phase I study and is advancing its preparations for a phase II study.
Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
